MedTrace Logo

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

NCT05092451 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-06

No results posted yet for this study

Summary

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.

Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.

Conditions

  • B-Cell Lymphoma
  • Myelodysplastic Syndromes (MDS)
  • Acute Myeloid Leukemia (AML)
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Hodgkin Lymphoma
  • T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia
  • Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia
  • Blastic Transformation of Chronic Myeloid Leukemia
  • Germ Cell Tumors

Interventions

DRUG

CAR.70/IL15-transduced CB-NK cells

Given by IV

DRUG

Fludarabine phosphate

Given by IV

DRUG

Cyclophosphamide

Given by IV

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • David Marin, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2026-08-31
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05092451 on ClinicalTrials.gov